Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tenaya Therapeutics Inc

0.4400
-0.0122-2.70%
Post-market: 0.44900.0090+2.05%19:59 EDT
Volume:1.84M
Turnover:801.50K
Market Cap:71.08M
PE:-0.34
High:0.4872
Open:0.4800
Low:0.4100
Close:0.4522
Loading ...

Promising Clinical Trial Results for TN-201 Support Buy Rating for Tenaya Therapeutics

TIPRANKS
·
31 Mar

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

GlobeNewswire
·
31 Mar

BRIEF-Tenaya Therapeutics Inc - On Mar 27, Co Approves Restructuring Plan - SEC Filing

Reuters
·
29 Mar

Tenaya Therapeutics Inc - on Mar 27, Co Approves Restructuring Plan - SEC Filing

THOMSON REUTERS
·
29 Mar

Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?

Insider Monkey
·
28 Mar

Tenaya Therapeutics, Inc. (TNYA): Among Stocks Receiving the Most Insider Love in March

Insider Monkey
·
25 Mar

Tenaya Therapeutics publishes preclinical data on TN-201 in cardiac function

TipRanks
·
25 Mar

Promising Developments in Tenaya Therapeutics’ TN-201 Program Justify Buy Rating

TIPRANKS
·
25 Mar

Tenaya Therapeutics Says Gene Therapy Candidate Improves Heart Function in Preclinical Trial

MT Newswires Live
·
24 Mar

Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) stock price dropped 13% last week; individual investors would not be happy

Simply Wall St.
·
24 Mar

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

GlobeNewswire
·
24 Mar

BRIEF-Tenaya Therapeutics files for mixed shelf offering of up to $300 mln

Reuters
·
22 Mar

Tenaya Therapeutics Inc: Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
22 Mar

Tenaya Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
14 Mar

Promising Clinical Data and Financial Stability Support Buy Rating for Tenaya Therapeutics Despite Price Target Reduction

TIPRANKS
·
13 Mar

Tenaya Therapeutics price target lowered to $5 from $18 at H.C. Wainwright

TIPRANKS
·
11 Mar

Promising Clinical Developments and Strategic Advancements Support Buy Rating for Tenaya Therapeutics

TIPRANKS
·
11 Mar

Tenaya Therapeutics reports Q4 EPS (28c), consensus (31c)

TIPRANKS
·
11 Mar

BRIEF-Tenaya Therapeutics Q4 Net Income USD -23.836 Million Vs. IBES Estimate USD -27.1 Million

Reuters
·
11 Mar

Tenaya Therapeutics Q4 Operating Expenses USD 24.652 Million

THOMSON REUTERS
·
11 Mar